J Halfvarson
Overview
Explore the profile of J Halfvarson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lamichhane N, Melas N, Bergqvist V, Ekholm N, Olen O, Ludvigsson J, et al.
Dig Dis Sci
. 2024 Apr;
69(6):2175-2183.
PMID: 38637457
Background: Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce. Aims: To assess treatment outcomes of patients with...
2.
Technological readiness and implementation of genomic-driven precision medicine for complex diseases
Franks P, Melen E, Friedman M, Sundstrom J, Kockum I, Klareskog L, et al.
J Intern Med
. 2021 Jul;
290(3):602-620.
PMID: 34213793
The fields of human genetics and genomics have generated considerable knowledge about the mechanistic basis of many diseases. Genomic approaches to diagnosis, prognostication, prevention and treatment - genomic-driven precision medicine...
3.
Kalla R, Adams A, Bergemalm D, Vatn S, Kennedy N, Ricanek P, et al.
J Crohns Colitis
. 2020 Nov;
15(5):699-708.
PMID: 33201212
Background: Success in personalized medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay [PEA] to identify diagnostic and prognostic...
4.
Vatn S, Carstens A, Kristoffersen A, Bergemalm D, Casen C, Moen A, et al.
Scand J Gastroenterol
. 2020 Aug;
55(10):1146-1156.
PMID: 32780604
Method: We examined faecal samples, using the GA-map™ Dysbiosis Test, to associate gut microbiota composition with Crohn's disease (CD) and ulcerative colitis (UC) and to identify markers for future biomarker...
5.
Kalla R, Adams A, Ventham N, Kennedy N, White R, Clarke C, et al.
J Crohns Colitis
. 2020 Jun;
14(12):1724-1733.
PMID: 32598439
Background: MicroRNAs [miRNAs] are cell-specific small non-coding RNAs that can regulate gene expression and have been implicated in inflammatory bowel disease [IBD] pathogenesis. Here we define the cell-specific miRNA profiles...
6.
Kalman T, Everhov A, Nordenvall C, Sachs M, Halfvarson J, Ekbom A, et al.
Br J Surg
. 2020 May;
107(11):1529-1538.
PMID: 32452553
Background: Treatment of patients with Crohn's disease has evolved in recent decades, with increasing use of immunomodulatory medication since 1990 and biologicals since 1998. In parallel, there has been increased...
7.
Chauhan A, Lalor T, Watson S, Adams D, Farrah T, Anand A, et al.
QJM
. 2019 Jun;
111(12):920-924.
PMID: 31222346
No abstract available.
8.
Eriksson C, Cao Y, Rundquist S, Zhulina Y, Henriksson I, Montgomery S, et al.
Aliment Pharmacol Ther
. 2017 Oct;
46(9):897-898.
PMID: 29023888
No abstract available.
9.
Eriksson C, Cao Y, Rundquist S, Zhulina Y, Henriksson I, Montgomery S, et al.
Aliment Pharmacol Ther
. 2017 Aug;
46(8):748-757.
PMID: 28833287
Background: Whether the epidemiology of ulcerative colitis (UC) has changed during recent decades is partly unknown. Aim: To depict temporal trends in the epidemiology and medical treatment of UC as...
10.
Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, et al.
Aliment Pharmacol Ther
. 2016 Dec;
45(4):519-532.
PMID: 28025840
Background: Real-life long-term data on infliximab treatment in ulcerative colitis are limited. Aim: To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors...